You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

15 Results
Drug
Other Name(s): Vesanoid®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Jun 2019
Drug
Other Name(s): Thalomid®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Jun 2019
Drug
Other Name(s): Stivarga®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Nov 2023
Regimen
Cancer Type:
Gastrointestinal, 
Gastrointestinal Stromal Tumours, 
Sarcoma, 
GIST
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    regorafenib - For the treatment of metastatic and/or unresectable gastrointestinal stromal tumors (GIST) in patients who have had disease progression on, or intolerance to,
    imatinib and sunitinib, according to specific criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
regorafenib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Aug 2023
Regimen
Cancer Type:
Gastrointestinal, 
Hepatobiliary / Liver / Bile Duct
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    regorafenib - For the treatment of unresectable, advanced hepatocellular carcinoma (HCC) according to clinical criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
regorafenib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Aug 2023
Drug
Other Name(s): Kisqali™
Quick Link(s):
Drug Monograph, Patient Info Sheet
Jan 2022
Drug
Other Name(s): Lonsurf®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Nov 2024
Regimen
Cancer Type:
Gastrointestinal, 
Gastrointestinal Stromal Tumours
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    ripretinib - For adult patients with advanced gastrointestinal stromal tumours (GIST) who have progression on or intolerance to imatinib, sunitinib and regorafenib
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
ripretinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Aug 2023
Regimen
Cancer Type:
Gastrointestinal, 
Gastric / Stomach
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    For the treatment of metastatic gastric cancer (mGC) or adenocarcinoma of the gastroesophageal junction (GEJ) in adult patients, according to clinical criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
trifluridine / tipiracil
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Nov 2022
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal, 
Small bowel and appendix
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    trifluridine / tipiracil - In combination with bevacizumab for treatment of metastatic colorectal cancer, according to clinical criteria
New Drug Funding Program
    Bevacizumab (Biosimilar) - In Combination with Trifluridine and Tipiracil for Previously Treated Metastatic Colorectal Cancer
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
trifluridine / tipiracil,
bevacizumab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Nov 2024
Drug
Other Name(s): Tukysa™
Quick Link(s):
Drug Monograph, Patient Info Sheet
Feb 2025
Drug
Other Name(s): Jakavi®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Mar 2025

Pages